Evolving portal hypertension through Baveno VII recommendations
- PMID: 37984701
- DOI: 10.1016/j.aohep.2023.101180
Evolving portal hypertension through Baveno VII recommendations
Abstract
The Baveno VII consensus workshop has provided several novel recommendations regarding the management of patients with clinically significant portal hypertension (CSPH). The expert panel summarized the existing data into simple clinical rules to aid clinicians in their clinical practice. The use of non-invasive tests (NITs), especially liver stiffness measurement (LSM), have gain an important role in daily practice. The use of LSM alone or in combination with platelet count can be used to rule-in and rule-out compensated advanced chronic liver disease (cACLD) and CSPH. Further decompensation events were defined as a prognostic stage associated with an even higher mortality than that associated with first decompensation. Moreover, the term hepatic recompensation was introduced in Baveno VII consensus implying a partial or complete regression of the functional and structural changes of cirrhosis after the removal of the underlying etiology. This review will summarize the reader main aspects of Baveno VII consensus regarding the use of NITs in cACLD, analyze further decompensation events, and evaluate recent recommendations for prophylaxis and management of liver decompensation events.
Keywords: Advanced chronic liver disease; Cirrhosis; Clinically significant portal hypertension; Liver stiffness; Non-selective beta-blockers.
Copyright © 2023 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.
Conflict of interest statement
Declaration of interests None.
Similar articles
-
Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.J Hepatol. 2024 Aug;81(2):248-257. doi: 10.1016/j.jhep.2024.03.005. Epub 2024 Mar 11. J Hepatol. 2024. PMID: 38479612
-
Utility of different Baveno criteria to detect esophageal varices irrespective of their size in patients with compensated cirrhosis.Indian J Gastroenterol. 2024 Jun;43(3):609-615. doi: 10.1007/s12664-023-01458-1. Epub 2023 Oct 16. Indian J Gastroenterol. 2024. PMID: 37840111
-
The Sequential Application of Baveno VII Criteria and VITRO Score Improves Diagnosis of Clinically Significant Portal Hypertension.Clin Gastroenterol Hepatol. 2023 Jul;21(7):1854-1863.e10. doi: 10.1016/j.cgh.2022.09.032. Epub 2022 Oct 14. Clin Gastroenterol Hepatol. 2023. PMID: 36244661
-
Baveno VII - Renewing consensus in portal hypertension.J Hepatol. 2022 Apr;76(4):959-974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30. J Hepatol. 2022. PMID: 35120736 Free PMC article. Review.
-
Non-invasive tools for compensated advanced chronic liver disease and portal hypertension after Baveno VII - an update.Dig Liver Dis. 2023 Mar;55(3):326-335. doi: 10.1016/j.dld.2022.10.009. Epub 2022 Nov 8. Dig Liver Dis. 2023. PMID: 36369196 Review.
Cited by
-
Cirrhotic cardiomyopathy and beyond: Underscoring the interaction between the liver and the heart.JHEP Rep. 2024 May 23;6(8):101114. doi: 10.1016/j.jhepr.2024.101114. eCollection 2024 Aug. JHEP Rep. 2024. PMID: 39105184 Free PMC article. No abstract available.
-
Portocaval shunts' role in gut microbiota and hepatic encephalopathy: The gut-to-brain pathway.World J Gastroenterol. 2024 Nov 21;30(43):4672-4676. doi: 10.3748/wjg.v30.i43.4672. World J Gastroenterol. 2024. PMID: 39575404 Free PMC article.
-
Comprehensive approach to esophageal variceal bleeding: From prevention to treatment.World J Gastroenterol. 2024 Nov 21;30(43):4602-4608. doi: 10.3748/wjg.v30.i43.4602. World J Gastroenterol. 2024. PMID: 39575399 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
